On September 21, 2026, Novo Nordisk used its Capital Markets Day to lay out a growth strategy that looks well beyond semaglutide, the molecule behind Ozempic and Wegovy that has driven most of the company's growth over the past several years. The company said it aims to launch at least five "multi-blockbuster" products by 2030 and generate more than DKK 150 billion in what it called risk-adjusted pipeline sales.
Diversifying Beyond a Single Molecule
Novo Nordisk's presentation framed the next several years as a deliberate move away from near-total reliance on semaglutide. In obesity, that includes CagriSema (the cagrilintide-semaglutide combination discussed elsewhere on this site, targeted for an early 2027 launch pending regulatory approval), cagrilintide as a standalone therapy, an amylin-pathway candidate called zenagamtide, and unnamed triple-agonist candidates still in earlier development.
New Disease Areas
The company also detailed pipeline assets outside metabolic disease entirely: FREHEMGO for hemophilia, etavopivat for sickle cell disease, and zaltinibar for hemato-renal disorders on the blood and endocrine side; efruxifermin, an FGF21-analog therapy, for advanced MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) on the liver side; and a set of inflammation-targeting cardiovascular assets aimed at IL-6 and NLRP3 pathways, two inflammatory signaling systems increasingly implicated in heart disease independent of cholesterol.
Oral Wegovy's Momentum
Novo also gave an update on its oral semaglutide pill, discussed in this site's earlier coverage of oral GLP-1 competition. The company said roughly 1.5 million patients are now using oral Wegovy, with U.S. prescriptions averaging about 285,000 per week, and that it plans to build manufacturing capacity for ten times its current patient volume by the end of the decade.
Why This Matters
The announcement comes as Novo Nordisk faces intensifying competition from Eli Lilly's tirzepatide franchise and oral orforglipron (branded Foundayo), both covered extensively elsewhere on this site, along with earlier-stage rivals developing their own oral and injectable GLP-1 and multi-agonist candidates. A revenue base concentrated almost entirely in one drug class carries real business risk if a competitor's product outperforms it or if pricing pressure compresses margins across the category, which is the backdrop for the "beyond semaglutide" framing Novo used at this event.
Reading Pipeline Announcements Critically
It's worth noting what a Capital Markets Day announcement is and isn't. These are forward-looking targets aimed primarily at investors, not regulatory filings or clinical trial results. Several of the named candidates, including zenagamtide, etavopivat, and the IL-6/NLRP3 cardiovascular assets, are still in early- or mid-stage development, and "risk-adjusted pipeline sales" is a financial projection method, not a guarantee. Whether any individual candidate reaches approval, and on what timeline, will depend on trial results this site will continue to track as they're reported.
The Bottom Line
Novo Nordisk's Capital Markets Day is a statement of strategic direction rather than a set of finished products. For patients and clinicians, the concrete, actionable news remains what's already approved (semaglutide in its various forms) or in late-stage trials with reported data, like CagriSema. The newer names on this list are pipeline candidates worth watching, not treatments available today, and none of them change anything about how currently approved GLP-1 medications should be used. Talk to a licensed physician about which currently available option, if any, is appropriate for your situation.